关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
" q: x" D/ I! s& b8 \    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
  \/ O, w2 V4 H3 L$ n
) ^7 C; g8 {3 d- y& W作者：来自澳大利亚
* D4 y, y' D0 T& m6 h6 j+ r来源：Haematologica. 2011.8.9.
7 A  W4 m2 E. W, A' pDear Group,
4 c3 c7 C- w2 @) j' J. [4 B
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
& ^8 ^1 f" _/ ^6 C, {/ ]therapies. Here is a report from Australia on 3 patients who went off Sprycel
# `! b7 I3 p) O+ cafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
6 S7 i" Z6 ~9 E: Sremain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
; j" b$ d  J) Z8 x4 i; O
The remarkable news about Sprycel cessation is that all 3 patients had failed
  J/ l" S( A6 v( R) [' YGleevec and Sprycel was their second TKI so they had resistant disease. This is
different from the stopping Gleevec trial in France which only targets patients
( `/ G' q2 C+ _+ E" X) p: L# {) ^6 zwho have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.

2 `. k" U, u' A3 ^# G' pBest Wishes,
, o8 W. C/ h$ }1 tAnjana
9 u* w2 \: ~/ a% l, @
3 L$ `' }7 E9 q

% t5 ~" ?0 V6 wHaematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
7 i7 W/ V% L- Y  y- edasatinib cessation, despite adverse disease features.
/ Y" m- @8 R0 \- e- e0 qRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
3 v3 W  e' o' p; w& i$ h0 vSource
Adelaide, Australia;

: U! R, L) g' h: x" l2 h, k3 |Abstract
, P% h( z: _4 \4 D5 o& vPatients with chronic myeloid leukemia, treated with imatinib, who have a
7 Z- c1 n* i* T$ K, e8 Ydurable complete molecular response might remain in CMR after stopping
! Q  f* X4 y9 w* l8 Ytreatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
% G" e5 b. ^. Rtreatment following imatinib failure. Two of the three patients remain in
complete molecular response more than 12 months after stopping dasatinib. In
) a$ e  p7 k% K1 i, othese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
9 I% W9 p* S1 z( |1 \& Bshow that the leukemic clone remains detectable, as we have previously shown in
9 J7 @; y* {! `& b* l- t/ p" Ximatinib-treated patients. Dasatinib-associated immunological phenomena, such as
" F8 j0 G8 Q, P4 jthe emergence of clonal T cell populations, were observed both in one patient
6 c+ m7 z+ E. R0 z% z$ ^who relapsed and in one patient in remission. Our results suggest that the
characteristics of complete molecular response on dasatinib treatment may be
/ b8 m0 v! G( R& Tsimilar to that achieved with imatinib, at least in patients with adverse
disease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事